Will AEterna Zentaris Inc NASDAQ:AEZS meet your expectations?
AEterna Zentaris Inc headquartered in Charleston, South Carolina, United States is reporting their earnings on 03/26/2019 after the bell. Street forecast for the quarter ending Feb 2019 is $-0.19.
According to stock market daily analyst this is Lower then same time previous year. AEterna Zentaris Inc, reported EPS for the same quarter last year was $-0.24.
About AEterna Zentaris Inc NASDAQ:AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women’s health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People’s Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
|% Change from 52 Week Low|
|% Change from 52 Week High|